Search
Close this search box.
    • Small Molecules
      • Discovery
    • Biologics
    • Other Drug Modalities
    • SynVent Integrated Drug Discovery
      • SynVent Integrated Drug Discovery

        SynVent is Syngene’s platform for fully integrated therapeutic discovery and development across large and small molecules. 

    • Industries
    • Emerging Biopharma
      • Emerging Biopharma

        Emerging biopharma work at the forefront of science, often venturing into disease areas where little or no real-world data exists to work with or regulatory frameworks to work within.

    • Dedicated Centers
      • Dedicated Centers

        Our Dedicated Centers offer dedicated multi-disciplinary scientific teams, support personnel, and a tailormade ring-fenced and fire-walled infrastructure as per client specifications to support their  R&D  goals

    • Center for Advanced Protein Studies (CAPS)
      • Center for Advanced Protein Studies (CAPS)

        Centre for Advanced Protein Studies [CAPS] is a state-of-the-art advanced national facility located in the Syngene campus, Bangalore.

  • Careers
Search
Close this search box.

Investor Fact Sheet

We aim to make a contribution to the evolution of scientific research using our skills, technology and experience to find solutions to the world’s most complex challenges.We harness the power of science and technology to  deliver integrated innovation with pace and efficiency across a diverse range of scientific domains. By providing access to the latest technology and highly trained scientists, underpinned by our values of integrity, excellence and professionalism, our aim is to be a trusted partner for clients seeking to explore the boundaries of science at affordable cost. Our services span the value chain from discovery to the clinic. Beyond the science, our strengths lie in our relentless pursuit of operational excellence; flexible business models; investment in data integrity; and passion for quality. We are proud to have partnerships that are deeply founded and nurtured over the years, delivering a level of commitment and understanding that drives innovation and scientific advances, thus linking our success to that of our clients and the people and patients they serve.

Key Figures (Consolidated, INR Million)

FY18
FY19
FY20
FY21
FY22
FY23
FY24
Revenue from operations
14,231
18,256
20,119
21,843
26,042
31,929
34,886
Other Income
618
751
816
646
528
709
906
Total income
14,849
19,007
20,935
22,489
26,570
32,638
35,792
Total expenses
9,583
12,888
13,940
15,125
18,081
22,585
24,742
EBITDA
5,266
6,119
6,995
7,364
8,489
10,053
11,050
EBITDA Margin %
35.46
32.19
33.41
32.70
31.94
30.80%
30.87%
Depreciation
1,314
1,642
2,193
2,745
3,097
3,665
4,259
Finance Cost
227
323
346
277
241
452
472
Profit Before Tax
3,725
4,154
4,456
4,342
5,151
5,936
6,319
Tax
671
838
794
521
940
1292
1133
Profit After Tax before exceptional items
3,054
3,316
3,662
3,821
4,211
4,644
5,186
Exceptional Items (net of tax)
459
228
-253
0
-86
Profit After Tax after exceptional items
3,054
3,316
4,121
4,049
3,958
4,644
5,100
Earning per share (INR) (Diluted)
15.43
16.67
10.35
10.11
9.82
11.51
12.69
Total Paid up Share Capital
2,000
2,000
4,000
4,000
4,008
4,014
4,020
Bonus Declared
1:1
Net cash from operating activities
4,462
6,304
6,771
7,012
5,806
8,235
10,421
Net cash from investing activities
-3,493
-6,465
-4,284
-6,281
-6,115
-6,564
-4,956
Net cash from financing activities
-787
-724
-2,255
580
-313
-3425
-5515
Cash and cash equivalents at the end of the year
2,527
1,652
1,930
3,233
2,618
895
857
Dividend Per Share (incl. interim and final dividends)
0.50
1.00
0.50
1.25
1.25

Your browser does not support this function.

To download, Please share your details

To view or email, Please share your details view

To download, Please share your details